109 related articles for article (PubMed ID: 7910024)
1. Demonstration by two-color flow cytometry that tyrosine kinase activity is required for down-modulation of the oncogenic neu receptor.
Brown VI; Shah N; Smith R; Hellman M; Jarett L; Mikami Y; Cohen E; Qian X; Greene MI
DNA Cell Biol; 1994 Feb; 13(2):193-209. PubMed ID: 7910024
[TBL] [Abstract][Full Text] [Related]
2. Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation.
Qian X; Dougall WC; Hellman ME; Greene MI
Oncogene; 1994 May; 9(5):1507-14. PubMed ID: 7908733
[TBL] [Abstract][Full Text] [Related]
3. Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy.
Dougall WC; Qian X; Greene MI
J Cell Biochem; 1993 Sep; 53(1):61-73. PubMed ID: 7901229
[TBL] [Abstract][Full Text] [Related]
4. Identification of p185neu sequences required for monoclonal antibody- or ligand-mediated receptor signal attenuation.
Qian X; O'Rourke DM; Drebin J; Zhao H; Wang Q; Greene MI
DNA Cell Biol; 1997 Dec; 16(12):1395-405. PubMed ID: 9428788
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts.
Kokai Y; Myers JN; Wada T; Brown VI; LeVea CM; Davis JG; Dobashi K; Greene MI
Cell; 1989 Jul; 58(2):287-92. PubMed ID: 2568888
[TBL] [Abstract][Full Text] [Related]
6. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation.
Lehtola L; Sistonen L; Koskinen P; Lehväslaiho H; Di Renzo MF; Comoglio PM; Alitalo K
J Cell Biochem; 1991 Jan; 45(1):69-81. PubMed ID: 1706346
[TBL] [Abstract][Full Text] [Related]
7. Mutation of the human neu protein facilitates down-modulation by monoclonal antibodies.
van Leeuwen F; van de Vijver MJ; Lomans J; van Deemter L; Jenster G; Akiyama T; Yamamoto T; Nusse R
Oncogene; 1990 Apr; 5(4):497-503. PubMed ID: 1970152
[TBL] [Abstract][Full Text] [Related]
8. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2.
Maier LA; Xu FJ; Hester S; Boyer CM; McKenzie S; Bruskin AM; Argon Y; Bast RC
Cancer Res; 1991 Oct; 51(19):5361-9. PubMed ID: 1680547
[TBL] [Abstract][Full Text] [Related]
9. A structural and kinetic comparison of proto-oncogenic and oncogenic neu holo-receptors expressed in insect cells.
LeVea CM; Myers JN; Dougall WC; Qian X; Greene MI
Receptor; 1993; 3(4):293-309. PubMed ID: 7908242
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation.
Ciardiello F; McGeady ML; Kim N; Basolo F; Hynes N; Langton BC; Yokozaki H; Saeki T; Elliott JW; Masui H
Cell Growth Differ; 1990 Sep; 1(9):407-20. PubMed ID: 1981145
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of cellular platelet-derived growth factor receptors induced by an activated neu receptor tyrosine kinase.
Lehtola L; Nistér M; Hölttä E; Westermark B; Alitalo K
Cell Regul; 1991 Aug; 2(8):651-61. PubMed ID: 1685673
[TBL] [Abstract][Full Text] [Related]
12. Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo.
Muthuswamy SK; Muller WJ
Oncogene; 1995 Nov; 11(9):1801-10. PubMed ID: 7478608
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of the early genomic growth factor response in neu oncogene-transformed cells.
Sistonen L; Koskinen PJ; Lehväslaiho H; Lehtola L; Bravo R; Alitalo K
Oncogene; 1990 Jun; 5(6):815-21. PubMed ID: 1972791
[TBL] [Abstract][Full Text] [Related]
14. Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation.
Qian X; Dougall WC; Fei Z; Greene MI
Oncogene; 1995 Jan; 10(1):211-9. PubMed ID: 7824275
[TBL] [Abstract][Full Text] [Related]
15. Structurally related class I and class II receptor protein tyrosine kinases are down-regulated by the same E3 protein coded for by human group C adenoviruses.
Kuivinen E; Hoffman BL; Hoffman PA; Carlin CR
J Cell Biol; 1993 Mar; 120(5):1271-9. PubMed ID: 8094718
[TBL] [Abstract][Full Text] [Related]
16. Signal transduction by the neu/erbB-2 receptor: a potential target for anti-tumor therapy.
Stancovski I; Peles E; Ben Levy R; Lemprecht R; Kelman Z; Goldman-Michael R; Hurwitz E; Bacus S; Sela M; Yarden Y
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):95-103. PubMed ID: 1356018
[TBL] [Abstract][Full Text] [Related]
17. Neu and its ligands: from an oncogene to neural factors.
Peles E; Yarden Y
Bioessays; 1993 Dec; 15(12):815-24. PubMed ID: 7908191
[TBL] [Abstract][Full Text] [Related]
18. Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins.
Wada T; Myers JN; Kokai Y; Brown VI; Hamuro J; LeVea CM; Greene MI
Oncogene; 1990 Apr; 5(4):489-95. PubMed ID: 1970151
[TBL] [Abstract][Full Text] [Related]
19. Ligand-independent oncogenic transformation by the EGF receptor requires kinase domain catalytic activity.
Danielsen AJ; Maihle NJ
Exp Cell Res; 2002 Apr; 275(1):9-16. PubMed ID: 11925101
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein.
Qian X; O'Rourke DM; Zhao H; Greene MI
Oncogene; 1996 Nov; 13(10):2149-57. PubMed ID: 8950982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
